Lanthanum Carbonate
drugOn this page
Also known as Dilanthanum tricarbonate hydrateFosrenolFoznolLanthanum (iii) carbonate hydrateLanthanum carbonate (la2(co3)3)Lanthanum carbonate anhydrousLanthanum carbonate hydrateLanthanum carbonate pentahydrateLanthanum carbonate tetrahydrateLanthanum sesquicarbonateLanthanum(3 ) carbonatePhosbloc
Summary
Lanthanum Carbonate (CHEMBL2096647) is an approved small molecule (ATC V03AE03); indicated across 4 conditions including chronic kidney disease and hyperphosphatemia.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: V03AE03
- Indications: 4 conditions
- Clinical trials: 33
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2096647 |
| Name | Lanthanum Carbonate |
| Type | Small molecule |
| Max phase | 4 |
| ATC | V03AE03 |
Also known as: Dilanthanum tricarbonate hydrate, Fosrenol, Foznol, Lanthanum (iii) carbonate hydrate, Lanthanum carbonate, Lanthanum carbonate (la2(co3)3), Lanthanum carbonate anhydrous, Lanthanum carbonate hydrate, Lanthanum carbonate pentahydrate, Lanthanum carbonate tetrahydrate, Lanthanum sesquicarbonate, Lanthanum(3 ) carbonate
Parent form; salt/anhydrous children: CHEMBL1909302
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
4 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| chronic kidney disease | 4 | MONDO:0005300 | EFO:0003884 |
| hyperphosphatemia | 3 | MONDO:0000328 | MONDO:0000328 |
| kidney disorder | 2 | MONDO:0005240 | EFO:0003086 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 33.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 9 |
| Not specified | 7 |
| PHASE4 | 6 |
| PHASE2 | 5 |
| PHASE1 | 5 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00160121 | PHASE4 | COMPLETED | Efficacy and Safety of Fosrenol in Treating Elevated Serum Phosphate Levels in Adults With End Stage Renal Disease |
| NCT00452478 | PHASE4 | TERMINATED | Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbonate) in Chronic Kidney Disease Stage 5 |
| NCT01845090 | PHASE4 | UNKNOWN | The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 |
| NCT02209636 | PHASE4 | COMPLETED | Phosphate Lowering in CKD Trial |
| NCT02237534 | PHASE4 | UNKNOWN | Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia |
| NCT03451019 | PHASE4 | COMPLETED | Different Effects of Non-calcium Phosphate Binders on Serum Calcium |
| NCT00150540 | PHASE3 | COMPLETED | A Long Term Study of Lanthanum Carbonate in Patients Requiring Dialysis Who Have Ived Lanthanum Carbonate in Previous Studies Defined by the Protocol. |
| NCT00150566 | PHASE3 | COMPLETED | Efficacy and Safety of Lanthanum in Controlling Serum Phosphate Levels in Subjects With End Stage Renal Disease Who Require Treatment for High Levels of Phosphate in Their Blood |
| NCT00151918 | PHASE3 | COMPLETED | Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal Disease |
| NCT00151931 | PHASE3 | COMPLETED | Efficacy and Tolerability of Treatment With Lanthanum Carbonate in Patients With End Stage Renal Disease Receiving Dialysis |
| NCT00841126 | PHASE3 | TERMINATED | Phase III Study to Investigate the Safety and Efficacy of Fermagate and Lanthanum Carbonate |
| NCT01514851 | PHASE3 | COMPLETED | Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate |
| NCT01518387 | PHASE3 | COMPLETED | Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis Patients |
| NCT01578200 | PHASE3 | COMPLETED | Outcome Study of Lanthanum Carbonate Compared With Calcium Carbonate in Hemodialysis Patients : Landmark Study |
| NCT03346369 | PHASE3 | UNKNOWN | Lanthanum Carbonate (Fosrenol®) to Reduce Oxalate Excretion in Patients With Secondary Hyperoxaluria and Nephrolithiasis |
| NCT00234702 | PHASE2 | COMPLETED | Efficacy and Safety of Lanthanum Carbonate in Reducing Serum Phosphorus Levels in Subjects With Stage 3 and 4 Chronic Kidney Disease |
| NCT00767637 | PHASE2 | COMPLETED | Long-term Treatment on BAY77-1931 (Lanthanum Carbonate) to Measure Lanthanum Concentrations in Bone |
| NCT01128179 | PHASE2 | COMPLETED | Effects of Lanthanum Carbonate on FGF-23 in Subjects With Stage 3 CKD |
| NCT01696279 | PHASE2 | COMPLETED | A Study to Assess the Pharmacokinetics of Lanthanum Carbonate, Investigate and Compare the Efficacy, Safety and Tolerability of Lanthanum Carbonate With Calcium Carbonate in Hyperphosphataemic Children and Adolescents With Chronic Kidney Disease on Dialysis |
| NCT02258074 | PHASE2 | COMPLETED | The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE |
| NCT04440696 | PHASE1/PHASE2 | UNKNOWN | To Evaluate the Patient Tolerance, Pharmacodynamics and Pharmacokinetics of Lanthanum Polystyrene Sulfonate Powder |
| NCT00875017 | PHASE1 | COMPLETED | Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENVELA® in Healthy Adult Volunteers |
| NCT00925704 | PHASE1 | COMPLETED | The Pharmacokinetics of Rocaltrol When Administered Alone or in Combination With Fosrenol or Renvela in Healthy Volunteers |
| NCT01289626 | PHASE1 | COMPLETED | Efficacy of Lanthanum Carbonate in Calciphylaxis |
| NCT02952040 | PHASE1 | COMPLETED | A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP1517 and Lanthanum Carbonate Hydrate |
| NCT03136705 | PHASE1 | COMPLETED | Healthy Combine Study |
| NCT00438932 | Not specified | COMPLETED | Low Phosphate Diets in Patients With Early Stages of Chronic Kidney Disease |
| NCT00557323 | Not specified | COMPLETED | Long-term Effect of Lanthanum Carbonate on Bone |
| NCT00785629 | Not specified | COMPLETED | A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD |
| NCT00843349 | Not specified | COMPLETED | Fibroblast Growth Factor-23 (FGF23) Reduction in Predialysis Chronic Kidney Disease (CKD) |
| NCT01130831 | Not specified | COMPLETED | Effect of Lanthanum Carbonate in Patients Previously Treated With Calcium-based Phosphate Binder Therapy |
| NCT01341678 | Not specified | COMPLETED | Circadian Rhythm Modulation by Dietary Phosphorus in Chronic Kidney Disease |
| NCT01581996 | Not specified | COMPLETED | Fosrenol and Phosphorus Balance - Lanthanum Carbonate |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: chronic kidney disease, hyperphosphatemia